ClinicalTrials.gg
RecruitingNCT07106684CAREMM-004Updated Oct 27, 2026

ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia

A Phase 2 interventional study of Autologous hematopoietic stem cell transplantation and BCMA CAR-T in Multiple Myeloma, Plasma Cell Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Primary conditionLeukemia, Plasma CellRegistry: Multiple MyelomaReclassifiedWhy we changed it
Registry
Multiple Myeloma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Plasma Cell
Why
  1. The study's listed conditions name Leukemia, Plasma Cell, a narrower term within Multiple Myeloma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Oct 27, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Leukemia, Plasma Cell with a site in China — 17 open to participants now, 18 under way, none of them phase 3. Leukemia, Plasma Cell · China.

Planned enrollment
11th of 19
20 · median 24
Started
2025
with 5 others
Phase 2
7 of 20
5 open now
Primary completion
2027-08
later than 12 of 17 live
Registered
15th of 20
by date
Lead sponsor
8 of 20
Institute of Hematology & Blood Diseases Hospital, China

Among the 20 studies in Leukemia, Plasma Cell with a site in China, this one is the 11th largest by planned enrollment of the 19 interventional ones that give a count, is one of 6 that started in 2025, is one of 7 in phase 2, reaches primary completion later than 12 of the 17 other live ones, and was the 15th registered.

Leukemia, Plasma Cell

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

Browse Leukemia, Plasma Cell studies →

Open to participants now

17 of the 20 studies in Leukemia, Plasma Cell with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Leukemia, Plasma Cell studies recruiting now, 12 (41%) set no upper age limit and 13 (45%) stop at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Leukemia, Plasma Cell with a site in China, or all of them as a file.
02

Study summary

This is a prospective, single-arm, phase II study to evaluate the efficacy and safety of autologous stem cell transplantation combined with BCMA CAR-T therapy followed by GPRC5D/CD3 bispecific antibody maintenance in transplant-eligible patients with primary plasma cell leukemia.

Read the detailed description

All subjects will receive standard induction therapy for up to four cycles prior to screening. Following response evaluation, those who meet the inclusion criteria will be enrolled. Enrolled patients will undergo autologous stem cell transplantation (ASCT) combined with BCMA CAR-T cell therapy, followed by GPRC5D/CD3 bispecific antibody therapy.

Patients who achieve a stringent complete response (sCR) and sustained MRD negativity (≥12 months) may enter a treatment-free observation phase or receive maintenance therapy for 24 months. Patients who experience MRD resurgence or loss of response during observation will resume maintenance therapy.

Patients who do not achieve both sCR and sustained MRD negativity (≥12 months) will continue GPRC5D/CD3 bispecific antibody therapy.

03

Conditions studied

  • Multiple Myeloma, Plasma Cell Leukemia

Browse trials for

Keywords

  • Plasma cell leukemia
  • CAR-T
  • ASCT
  • BiTEs
04

In context

Leukemia, Plasma Cell Reclassified

60 studies on the registry are indexed under Leukemia, Plasma Cell; 33 are open to participants now.

This study's planned enrollment of 20 is below the median of 27 across 53 interventional studies indexed under Leukemia, Plasma Cell.

Browse Leukemia, Plasma Cell studies →

Lead sponsor

Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 414 studies on the registry; 292 are open to participants now.

Compared within Leukemia, Plasma Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Multiple Myeloma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years and ≤ 70 years.
  2. Participants with documented newly-diagnosed primary plasma cell leukemia according to IMWG diagnostic criteria.
  3. at screening, defined as: Serum M-protein level ≥1.0 g/dL or urine M-protein level ≥200 mg/24 hours; or Light chain MM without measurable disease in serum or urine: serum Ig free-light chain (FLC) ≥10 mg/dL and abnormal serum Ig kappa lambda FLC ratio.
  4. Patients deemed eligible for high-dose chemotherapy with .
  5. Tumor cells were BCMA and GPRC5D positive.
  6. Serum total \<2 x (ULN), serum and ALT \<3 x ULN, ≥ 30mL/min (Cockroft-Gault formula).
  7. /Assent: All subjects have the ability to understand and the willingness to sign a written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Active amyloidosis.
  2. Central nervous system involvement.
  3. Prior BCMA-targeted therapy or CAR-T therapy.
  4. Active or virus infection.
  5. Known infection.
  6. \<6 months.
  7. Woman who are pregnant or breastfeeding
  8. Evidence of uncontrolled dysfunction of heart, lung, brain, and other important organs.
  9. Any other conditions that are not eligible for the trial in the judgement of the principal investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance

    Patients will receive induction therapy, undergo ASCT followed by BCMA CAR-T infusion. Three month after CAR-T cell infusion, patients will begin GPRC5D/CD3 BiTEs maintenance therapy.

    Procedure: Autologous hematopoietic stem cell transplantation · Biological: BCMA CAR-T · Drug: GPRC5D/CD3 BiTEs

Interventions

  • ProcedureAutologous hematopoietic stem cell transplantation

    Patients receive transplantation conditioning followed by autologous hematopoietic stem cell transplantation after successful stem cell mobilization and collection.

  • BiologicalBCMA CAR-T

    Patients will receive BCMA CAR-T single dose infusion 3 days after ASCT.

  • DrugGPRC5D/CD3 BiTEs

    Patients will receive GPRC5D/CD3 BiTEs maintenance therapy at a dose of 54 μg/kg every 4 weeks, starting 3 months after BCMA CAR-T infusion.

07

What researchers measure

Primary outcomes

  1. Sustained MRD-negative rate

    Rate of patients achieving sustained MRD negativity for more than 12 months

    Time frame: Up to 2 year

  2. MRD negativity rate

    Rate of patients achieving MRD negativity

    Time frame: Up to 2 years

Secondary outcomes

  1. Safety and Tolerability

    The incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Up to 2 year

  2. Complete response rate (CRR)

    CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria

    Time frame: Up to 2 years

  3. Progression free survival (PFS)

    Progression free survival is defined as the time from the date of diagnosis to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first

    Time frame: Up to 3 year

  4. Overall survival (OS)

    Overall survival is defined as the time from the date of diagnosis to the date of death due to any cause

    Time frame: Up to 5 year

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 23 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 6, 2025
StartActual
Aug 9, 2025
Primary completionEst.
Aug 1, 2027
CompletionEst.
Aug 1, 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 10, 2025→Aug 9, 2025 (actual)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Start date Aug 10, 2025→Aug 9, 2025 (now actual)
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07106684
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Aug 9, 2025
Primary completion
Aug 1, 2027 (estimated)
Completion
Aug 1, 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Gang An, PhD&MD
Contact
angang@ihcams.ac.cn
86-022-23909171

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion